Nature Communications

Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial

2025-07-01

Full text

DOI https://doi.org/10.1038/s41467-025-61213-2